How much of Innoviva's $125 million authorization has been used?

Through the end of Q2 2026, Innoviva has spent $56.4 million repurchasing 2.6 million shares, leaving approximately $68.6 million (55%) of the authorization remaining. The company is executing the program over time rather than as a single transaction.

What was the average price Innoviva paid per share in Q2 2026?

During Q2 2026, the company repurchased 1.4 million shares for $31.4 million, equating to an average price of approximately $22.36 per share, reflecting cumulative execution at that price point during the quarter.

Why is Innoviva repurchasing shares despite market uncertainty?

Management stated that the buybacks reflect 'continued conviction in the long-term prospects of our diversified business model.' The company cited durable cash generation from its royalty portfolio ($59.8 million in Q2), growing net product sales (46% year-over-year), and strategic healthcare investments as confidence drivers.

How does the buyback compare to Innoviva's cash position and capital deployment?

Innoviva held $570.4 million in cash as of June 30, 2026. Beyond buybacks, the company deployed $55 million in the quarter to support its strategic healthcare asset portfolio, suggesting a balanced approach to returning and reinvesting capital.

Does the filing specify an expiration date or execution method for the buyback program?

The filing does not disclose the execution mechanism (e.g., Rule 10b-18, ASR, 10b5-1 plan) or an expiration date for the $125 million authorization, treating these as standard operational details.

What impact does the buyback have on Innoviva's share count?

The repurchase of 2.6 million shares since inception modestly reduces the share count, supporting per-share metrics, though the company remains a micro-cap biopharmaceutical with approximately 73.4 million basic shares outstanding as of Q2 2026.

INVA 8-K Filed 2026-08-05 Execution disclosure

Innoviva repurchased 1.4M shares for $31.4M in Q2 2026

Company has now repurchased 2.6M shares under $125M authorization; total spent $56.4M to date.

Shares repurchased1.4M

Avg price paid$22.36

Remaining$69M

MechanismNot specified

What the filing says

Innoviva, Inc. (NASDAQ: INVA) reported that during the second quarter of 2026, it repurchased 1,403,247 shares for $31.4 million under its $125 million share repurchase program. Since inception of the program through the end of Q2 2026, the company has repurchased a total of 2,602,168 shares for $56.4 million, reflecting accumulated execution of approximately 45% of the authorized amount.

The company disclosed this capital allocation activity in its Q2 2026 earnings press release filed as an exhibit to its 8-K filing. Management noted that "our continued activity under the share repurchase program reflects our sustained conviction in the long-term prospects of our diversified business model — one that combines durable cash generation, strong operating revenue growth, and value creation in high-potential strategic opportunities." The execution mechanism was not explicitly specified in the filing.

As of June 30, 2026, Innoviva maintained cash and cash equivalents of $570.4 million, supporting ongoing capital deployment. The company generated operating cash flow of $87.3 million during the first six months of 2026, with total revenue of $119.6 million in Q2 driven by royalty revenue of $59.8 million and net product sales of $51.8 million.

During the second quarter of 2026, Innoviva repurchased 1,403,247 shares for $31.4 million under its $125 million share repurchase program. Since inception, and through the end of the second quarter, the Company has repurchased 2,602,168 shares for $56.4 million, reflecting the Company's continued confidence in its intrinsic value and long-term outlook. — Innoviva, Inc. 8-K filing · View on SEC EDGAR →

What this means

Innoviva's Q2 buyback activity reflects continued execution under its $125 million authorization, with roughly 55% remaining available. The company repurchased approximately 1.4 million shares at an average price of $22.36 per share, reducing the weighted-average share count modestly while preserving substantial cash reserves ($570.4 million) to support operations, strategic investments, and potential future capital returns. The filing does not disclose whether repurchases were conducted via Rule 10b-18 open-market purchases or another mechanism, nor does it specify an expiration date for the authorization.

Frequently asked questions

How much of Innoviva's $125 million authorization has been used?: Through the end of Q2 2026, Innoviva has spent $56.4 million repurchasing 2.6 million shares, leaving approximately $68.6 million (55%) of the authorization remaining. The company is executing the program over time rather than as a single transaction.
What was the average price Innoviva paid per share in Q2 2026?: During Q2 2026, the company repurchased 1.4 million shares for $31.4 million, equating to an average price of approximately $22.36 per share, reflecting cumulative execution at that price point during the quarter.
Why is Innoviva repurchasing shares despite market uncertainty?: Management stated that the buybacks reflect 'continued conviction in the long-term prospects of our diversified business model.' The company cited durable cash generation from its royalty portfolio ($59.8 million in Q2), growing net product sales (46% year-over-year), and strategic healthcare investments as confidence drivers.
How does the buyback compare to Innoviva's cash position and capital deployment?: Innoviva held $570.4 million in cash as of June 30, 2026. Beyond buybacks, the company deployed $55 million in the quarter to support its strategic healthcare asset portfolio, suggesting a balanced approach to returning and reinvesting capital.
Does the filing specify an expiration date or execution method for the buyback program?: The filing does not disclose the execution mechanism (e.g., Rule 10b-18, ASR, 10b5-1 plan) or an expiration date for the $125 million authorization, treating these as standard operational details.
What impact does the buyback have on Innoviva's share count?: The repurchase of 2.6 million shares since inception modestly reduces the share count, supporting per-share metrics, though the company remains a micro-cap biopharmaceutical with approximately 73.4 million basic shares outstanding as of Q2 2026.

execution biopharmaceutical royalties rule-10b-18-inferred q2-2026 micro-cap

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.